Treatment results with oral Rocaltrol pulse among patients with secondary hyperparathyroidism in hemodialysis ward

Background and Objective: Renal osteodystrophy is one of the most important complications of ESRD (End Stage Renal Disease). Prescription of calcium, low phosphate diet and rocaltrol are essential in these patients. The aim of this study was to determine the prevalence of renal osteodystrophy and se...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	M Malek, M Fakharian Kashani
Formato:	article
Lenguaje:	EN FA
Publicado:	Babol University of Medical Sciences 2004
Materias:	secondary hyperparathyroidism renal osteodystrophy hemodialysis rocaltrol ipth oral pulse Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/4190f83d774a4994ac2cb7f78b78aeb2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4190f83d774a4994ac2cb7f78b78aeb2
record_format	dspace
spelling	oai:doaj.org-article:4190f83d774a4994ac2cb7f78b78aeb22021-11-10T09:15:56ZTreatment results with oral Rocaltrol pulse among patients with secondary hyperparathyroidism in hemodialysis ward1561-41072251-7170https://doaj.org/article/4190f83d774a4994ac2cb7f78b78aeb22004-01-01T00:00:00Zhttp://jbums.org/article-1-2736-en.htmlhttps://doaj.org/toc/1561-4107https://doaj.org/toc/2251-7170Background and Objective: Renal osteodystrophy is one of the most important complications of ESRD (End Stage Renal Disease). Prescription of calcium, low phosphate diet and rocaltrol are essential in these patients. The aim of this study was to determine the prevalence of renal osteodystrophy and secondary hyperparathyroidism in ESRD patients were covered by Semnan- Fatemieh hemodialysis center and detect the oral rocaltrol pulse response on secondary hyperparathyroidism and renal osteodystrophy in some of these patients. Methods: In first step, 31 patients with ESRD checked for serum calcium (Ca2+) phosphorous (P), alkaline phosphatase and iPTH (IRMA) and bone deformity in bone x-ray from 2000-2001. In second step, 12 patients were categorized in three groups according to iPTH level and treated with 1, 2, 4 microgram oral-rocaltrol pulse, three times a week for 6 months, respectively. Then Ca2+, P, alkaline phosphatase, iPTH levels and bone graphy compared with before treatment results. Findings: From 31 patients with age average 52±17.7 and hemodialysis duration average 36±22.3 months, 3.5 Percent had Ca2+ level equal or higher than 10.4 mg/dl, 77.3 percent had P level equal or higher than 4.5 mg/dl, 80.6 percent had iPTH level higher than 120 pg/ml and 72.4 percent had alkaline phosphatase level higher than 175 Iu/l. No meaningful correlation observed between hemodialysis duration with serum Ca2+, P and alkaline phosphatase level. In 12 patients treated with oral rocaltrol pulse, meaningful differences observed only between serum iPTH level before and after treatment (P<0.003). Conclusion: In most studied patients, serum P and iPTH level was extremely high that suggest poor control of P and hyperparathyroidism. Oral rocaltrol pulse prescription for 6 months decreased iPTH level but had no effect on Ca2+, P and alkaline phosphatase.M MalekM Fakharian KashaniBabol University of Medical Sciencesarticlesecondary hyperparathyroidismrenal osteodystrophyhemodialysisrocaltrolipthoral pulseMedicineRMedicine (General)R5-920ENFAMajallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, Vol 6, Iss 1, Pp 32-37 (2004)
institution	DOAJ
collection	DOAJ
language	EN FA
topic	secondary hyperparathyroidism renal osteodystrophy hemodialysis rocaltrol ipth oral pulse Medicine R Medicine (General) R5-920
spellingShingle	secondary hyperparathyroidism renal osteodystrophy hemodialysis rocaltrol ipth oral pulse Medicine R Medicine (General) R5-920 M Malek M Fakharian Kashani Treatment results with oral Rocaltrol pulse among patients with secondary hyperparathyroidism in hemodialysis ward
description	Background and Objective: Renal osteodystrophy is one of the most important complications of ESRD (End Stage Renal Disease). Prescription of calcium, low phosphate diet and rocaltrol are essential in these patients. The aim of this study was to determine the prevalence of renal osteodystrophy and secondary hyperparathyroidism in ESRD patients were covered by Semnan- Fatemieh hemodialysis center and detect the oral rocaltrol pulse response on secondary hyperparathyroidism and renal osteodystrophy in some of these patients. Methods: In first step, 31 patients with ESRD checked for serum calcium (Ca2+) phosphorous (P), alkaline phosphatase and iPTH (IRMA) and bone deformity in bone x-ray from 2000-2001. In second step, 12 patients were categorized in three groups according to iPTH level and treated with 1, 2, 4 microgram oral-rocaltrol pulse, three times a week for 6 months, respectively. Then Ca2+, P, alkaline phosphatase, iPTH levels and bone graphy compared with before treatment results. Findings: From 31 patients with age average 52±17.7 and hemodialysis duration average 36±22.3 months, 3.5 Percent had Ca2+ level equal or higher than 10.4 mg/dl, 77.3 percent had P level equal or higher than 4.5 mg/dl, 80.6 percent had iPTH level higher than 120 pg/ml and 72.4 percent had alkaline phosphatase level higher than 175 Iu/l. No meaningful correlation observed between hemodialysis duration with serum Ca2+, P and alkaline phosphatase level. In 12 patients treated with oral rocaltrol pulse, meaningful differences observed only between serum iPTH level before and after treatment (P<0.003). Conclusion: In most studied patients, serum P and iPTH level was extremely high that suggest poor control of P and hyperparathyroidism. Oral rocaltrol pulse prescription for 6 months decreased iPTH level but had no effect on Ca2+, P and alkaline phosphatase.
format	article
author	M Malek M Fakharian Kashani
author_facet	M Malek M Fakharian Kashani
author_sort	M Malek
title	Treatment results with oral Rocaltrol pulse among patients with secondary hyperparathyroidism in hemodialysis ward
title_short	Treatment results with oral Rocaltrol pulse among patients with secondary hyperparathyroidism in hemodialysis ward
title_full	Treatment results with oral Rocaltrol pulse among patients with secondary hyperparathyroidism in hemodialysis ward
title_fullStr	Treatment results with oral Rocaltrol pulse among patients with secondary hyperparathyroidism in hemodialysis ward
title_full_unstemmed	Treatment results with oral Rocaltrol pulse among patients with secondary hyperparathyroidism in hemodialysis ward
title_sort	treatment results with oral rocaltrol pulse among patients with secondary hyperparathyroidism in hemodialysis ward
publisher	Babol University of Medical Sciences
publishDate	2004
url	https://doaj.org/article/4190f83d774a4994ac2cb7f78b78aeb2
work_keys_str_mv	AT mmalek treatmentresultswithoralrocaltrolpulseamongpatientswithsecondaryhyperparathyroidisminhemodialysisward AT mfakhariankashani treatmentresultswithoralrocaltrolpulseamongpatientswithsecondaryhyperparathyroidisminhemodialysisward
_version_	1718440186090618880

Treatment results with oral Rocaltrol pulse among patients with secondary hyperparathyroidism in hemodialysis ward

Ejemplares similares